Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Duan L, et al
In the SURMOUNT-1 study, a phase 3 clinical trial in obese patients, randomized participants in a 1:1:1:1 ratio to tirzepatide (5, 10, 15 mg) or placebo over 72 weeks, significant weight reductions were observed at 72 weeks: 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg, compared to 3.1% for placebo [18]
In particular, in vitro eryptosis was induced in RBCs from healthy volunteers after exposure to plasma from septic patients [126]
The cells were blocked with the immunostaining blocking buffer (Beyotime, China) for 1 h at room temperature, incubated with primary antibody against myosin heavy chain (1:1,000, Sigma-Aldrich, USA) at 4 C overnight and then with Goat anti-Mouse IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 594 (1:400, Invitrogen, USA) for 1 h at room temperature
